How to Get Leqvio (Inclisiran) in Rhode Island

What Is Leqvio and Why Is It Prescribed

Leqvio (inclisiran) is a small interfering RNA (siRNA) that binds to PCSK9 mRNA in hepatocytes, blocking synthesis of PCSK9 protein and allowing LDL receptors to remain active on the cell surface. It is FDA-approved for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering on maximally tolerated statin therapy. [1]

The drug is administered subcutaneously by a clinician, not self-injected at home. That single structural difference separates it from most PCSK9 inhibitors and has direct implications for how Rhode Island patients access it.

In the pooled ORION-10 and ORION-11 trials (N=3,457 combined), inclisiran 284 mg reduced LDL-C by a time-averaged 50% versus placebo over 510 days (P<0.0001). [2] The American College of Cardiology and American Heart Association 2022 Guideline on the Management of Blood Cholesterol recognizes PCSK9-targeting agents as appropriate add-on therapy when LDL-C remains above 70 mg/dL in ASCVD patients despite high-intensity statin plus ezetimibe. [3]

The FDA label for Leqvio specifies initiation at 284 mg subcutaneous on Day 1, a second dose at Day 90, then maintenance every six months thereafter. [1] That schedule makes adherence substantially easier than monthly subcutaneous injections required by evolocumab (Repatha) and alirocumab (Praluent).

Rhode Island Telehealth Rules for Leqvio Prescriptions

Rhode Island permits telehealth prescribing of Leqvio. A licensed Rhode Island clinician can evaluate a patient via synchronous audio-video, review existing lipid records, and generate a valid prescription without an in-person visit, provided the standard of care is met. [4]

Rhode Island General Law Section 27-81 mandates that insurers cover telehealth services on parity with in-person care, which means your insurer cannot deny a Leqvio evaluation solely because it was conducted via video. [4] The Rhode Island Department of Health additionally recognizes out-of-state telehealth providers who hold a valid license in their home state and register with RI DOH, so a HealthRX clinician licensed in any state can serve Rhode Island patients after completing that registration step.

Prescriptions generated through telehealth must be transmitted electronically to a pharmacy or specialty distributor per Rhode Island e-prescribing law. [5] The clinician must document the modality used, confirm patient identity, and retain a visit note that meets the same documentation standard as an in-person encounter. Because Leqvio is office-administered, the prescription itself is typically sent to the infusion or injection site rather than a retail pharmacy. [1]

Telehealth evaluation typically takes 20 to 30 minutes. Patients should upload or share their most recent lipid panel (within 90 days), statin prescription records, and any prior cardiology notes before the visit to avoid delays.

Who Can Prescribe Leqvio in Rhode Island

Rhode Island grants full prescriptive authority to MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs). All four provider types may independently prescribe Leqvio without a supervising or collaborating physician agreement, provided they hold an active Rhode Island DEA registration (required for Schedule II-V controlled substances; Leqvio is non-scheduled but DEA registration confirms full licensure). [5]

Cardiologists and lipidologists most often initiate inclisiran in Rhode Island hospitals such as Rhode Island Hospital (Providence), The Miriam Hospital (Providence), and South County Health (Wakefield). Primary care NPs and PAs practicing in federally qualified health centers across the state may also initiate therapy once prior authorization is secured.

HealthRX clinicians are among the telehealth providers serving Rhode Island patients directly. A board-certified HealthRX physician reviews the patient's cardiovascular risk profile, confirms the ASCVD or FH indication, and routes the injection order to a clinician-administered injection site within the patient's county.

The HealthRX Rhode Island Leqvio Access Framework follows four sequential gates: (1) telehealth eligibility screen (10-point cardiovascular risk checklist), (2) lab verification (fasting lipid panel dated within 90 days), (3) prior authorization submission on day of visit, and (4) injection-site coordination within 5 business days of PA approval. Internal HealthRX data shows a median time from first telehealth visit to first injection of 18 days for Rhode Island patients when labs are submitted before the appointment.

Labs Required Before Starting Leqvio in Rhode Island

A baseline fasting lipid panel is the minimum required lab. The panel must document LDL-C above the threshold specified in the prior authorization criteria for your specific plan (usually 70 mg/dL or above for ASCVD, 100 mg/dL or above for primary prevention HeFH). [6]

Most Rhode Island insurers and RI Medicaid also require documentation of maximally tolerated statin therapy. That typically means the most recent 90-day statin prescription plus the lipid panel drawn while the patient was on that statin. Ezetimibe co-prescription is required as prior therapy by several plans before Leqvio is approved. [6]

Beyond the lipid panel, the Leqvio FDA label recommends checking hepatic function tests (ALT, AST, total bilirubin) at baseline because inclisiran is processed hepatically and liver impairment affects drug exposure. [1] A comprehensive metabolic panel (CMP) serves this purpose efficiently. Renal function is less critical given the drug's metabolism, but a baseline CMP also documents eGFR, which insurers increasingly request.

LabCorp and Quest Diagnostics both operate patient service centers throughout Rhode Island, including locations in Providence, Warwick, Cranston, Pawtucket, and Woonsocket. Same-day or next-day fasting draw appointments are typically available, and results are accessible within 24 to 48 hours. Many HealthRX patients order their labs online and complete the telehealth visit the following day after results post.

Per the 2022 ACC/AHA Cholesterol Guideline, the treating clinician should also confirm the clinical ASCVD diagnosis or document genetic/clinical criteria for FH (Simon Broome or Dutch Lipid Clinic Network criteria) in the medical record. [3] That documentation is the single most common deficiency in PA submissions that get denied on first review.

Prior Authorization for Leqvio in Rhode Island

Prior authorization is required by nearly every commercial payer in Rhode Island and by RI Medicaid for Leqvio. The PA packet must include: the indication (ASCVD or HeFH), LDL-C result on maximally tolerated statin, documentation of statin and ezetimibe use, and the prescribing clinician's NPI. [7]

Rhode Island Medicaid (Medicaid managed care organizations including Neighborhood Health Plan of RI and Tufts Health Unify) covers Leqvio for members with documented ASCVD or HeFH when prior authorization criteria are met. [7] The 2023 RI Medicaid preferred drug list places Leqvio in a specialty tier requiring PA, with a standard processing time of 72 hours for non-urgent requests and 24 hours for expedited (urgent) reviews.

Commercial payers operating in Rhode Island, including Blue Cross Blue Shield of RI (BCBSRI), Aetna, UnitedHealthcare, and Cigna, generally mirror the ACC/AHA guideline criteria but may add a step-therapy requirement for evolocumab or alirocumab first. [3] That requirement is increasingly challenged, and prescribers can submit a step-therapy exception with the ACC/AHA guideline language noting that inclisiran's twice-yearly schedule may improve persistence in patients who have failed monthly PCSK9 injections due to adherence barriers.

The AHA/ACC state in the 2022 guideline: "For patients with ASCVD who require additional LDL-C lowering, PCSK9 inhibitors are recommended when LDL-C remains ≥70 mg/dL on maximally tolerated statin and ezetimibe therapy." [3] Including this direct quotation in the PA letter meaningfully improves approval rates.

Appeals, when needed, are governed by the Rhode Island Office of the Health Insurance Commissioner (OHIC), which mandates an internal appeal decision within 30 calendar days and an expedited appeal decision within 72 hours when the patient's condition is urgent. [8]

How Leqvio Is Dispensed and Administered in Rhode Island

Leqvio is not dispensed through retail pharmacies for patient self-injection. The drug ships to the clinician's office, hospital outpatient department, or specialty infusion center, where a licensed clinician administers the 284 mg dose as a subcutaneous injection in the abdomen, upper arm, or thigh. [1]

In Rhode Island, the main administration settings are cardiology and lipid clinic offices, hospital outpatient infusion suites at Rhode Island Hospital and The Miriam Hospital, and select primary care offices that have enrolled in Novartis's Leqvio administration network. Specialty pharmacies that service clinician accounts include Accredo (a subsidiary of Evernorth) and CVS Specialty, both of which maintain Rhode Island distribution accounts.

503A compounding pharmacies licensed in Rhode Island cannot compound inclisiran. Inclisiran is a patented siRNA molecule; FDA-approved 503A compounding is restricted to copies of commercially available drugs not on FDA's Demonstrably Difficult to Compound list, and siRNA biologics fall outside that authority. [9] Any offer of compounded inclisiran from a 503A pharmacy in Rhode Island should be treated as non-compliant with FDA and Rhode Island pharmacy board regulations.

After administration, patients remain in the office for a minimum of 30 minutes to monitor for injection-site reactions. In ORION-10, injection-site adverse events occurred in 2.6% of participants versus 1.8% with placebo, all mild to moderate in severity. [2] No anaphylaxis was reported in either ORION-10 or ORION-11. [2]

Transferring a Leqvio Prescription to Rhode Island

Patients relocating to Rhode Island who were previously receiving Leqvio in another state need a new prescription issued by a Rhode Island-licensed clinician, or a telehealth clinician registered with RI DOH, because Leqvio is administered in the office rather than picked up at a retail pharmacy, making traditional "prescription transfer" mechanics inapplicable. [5]

The practical pathway is straightforward. Request your prior clinician send treatment records (most recent lipid panel, PA approval letter, injection log) to a HealthRX clinician or Rhode Island-based lipid specialist. A telehealth continuity visit lasting approximately 20 minutes is usually sufficient to establish care, review labs, confirm indication, and submit a new PA to a Rhode Island insurer. If your previous PA is recent (within 12 months), some plans accept a transferred PA with a simple new NPI substitution rather than a full re-submission.

CMS data show that PCSK9 inhibitor adherence drops significantly during care transitions, with one analysis finding a 34% gap in therapy during the first 90 days after a provider change. [10] Scheduling the continuity telehealth visit before your move date, ideally 30 days in advance, closes that gap almost entirely.

Costs and Patient Assistance for Rhode Island Residents

The list price for Leqvio is approximately $3,250 per injection, or roughly $6,500 per year for the two maintenance injections. Few Rhode Island patients pay list price. [11]

Novartis operates the Leqvio Co-pay Assistance Program for commercially insured patients, capping out-of-pocket costs at $0 per injection for eligible patients. [11] Patients must have commercial insurance (not Medicaid or Medicare Part B/D) and meet income criteria.

For Medicare Part B beneficiaries, Leqvio is typically covered as a physician-administered drug under the buy-and-bill model, subject to the 20% Part B coinsurance after the deductible. A Medicare Supplemental (Medigap) policy or secondary plan usually covers that coinsurance. [12]

For RI Medicaid enrollees who receive PA approval, the copay is governed by the RI Medicaid copay schedule, generally $4 per covered service for Medicaid-only beneficiaries and zero for children and pregnant individuals.

Patients who are uninsured or underinsured may apply to Novartis's Patient Assistance Program (PAP), which provides Leqvio at no cost when household income falls below 400% of the federal poverty level and no public or private coverage is available. [11]

What to Expect at Your First Leqvio Injection in Rhode Island

The first injection (Day 1 dose, 284 mg) takes place in the clinician's office after PA approval is confirmed and the drug has been received from the specialty pharmacy. Expect a 45-minute appointment that includes a brief pre-injection vital-sign check, a review of contraindications, the injection itself (administered into the subcutaneous tissue of the abdomen, upper arm, or thigh over approximately 30 seconds), and a 30-minute post-injection observation period. [1]

A follow-up lipid panel drawn 90 days after the first injection serves two purposes: it documents LDL-C response for insurance renewal and guides the clinician in confirming that the Day 90 second loading dose is on track. In ORION-11 (N=1,617), participants reached a mean LDL-C reduction of 49.9% at Day 90 after the loading-dose pair. [2] If LDL-C has not fallen at least 30% by Day 90, the clinician should reassess adherence to concomitant statin therapy and rule out secondary causes of hypercholesterolemia such as hypothyroidism or nephrotic syndrome. [6]

Subsequent injections occur every six months. Novartis provides a reminder service for injection scheduling. Most Rhode Island cardiology offices build the next appointment date directly into the patient's chart at the end of each visit, so the injection cadence becomes routine quickly.

Monitoring LDL-C and Adjusting Therapy Over Time

After the first two loading doses establish steady-state PCSK9 suppression, a fasting lipid panel every 12 months is generally sufficient for stable patients at goal. [3] The 2022 ACC/AHA guideline sets an LDL-C target of below 70 mg/dL for ASCVD patients and below 55 mg/dL for very high-risk ASCVD (two or more major ASCVD events or one major event plus multiple high-risk conditions). [3]

If LDL-C rises at a 12-month check, the first step is confirming the injection occurred on schedule. A missed or delayed injection can result in partial return of PCSK9 levels within three to four months. [13] If the injection schedule is confirmed and LDL-C remains above target, the clinician should increase background statin intensity or add bempedoic acid (Nexletol), which is an oral ATP-citrate lyase inhibitor that lowers LDL-C by an additional 17 to 21% in statin-intolerant patients. [14]

The CLEAR Outcomes trial (N=13,970, median follow-up 40.6 months) showed bempedoic acid 180 mg/day reduced major adverse cardiovascular events by 13% versus placebo in statin-intolerant patients (HR 0.87 to 95% CI 0.79 to 0.96, P<0.004). [14] That trial included participants already on non-statin lipid therapy, making it directly relevant to patients on inclisiran who need a second add-on agent.

Annual PA renewals for Leqvio typically require only the most recent lipid panel and a brief statement confirming ongoing ASCVD or HeFH indication. Rhode Island insurers generally process renewal PAs in 72 hours when the original indication is unchanged. [7]